0000000000066710

AUTHOR

Jordi Caplliure-llopis

showing 5 related works from this author

Poor Bone Quality in Patients With Amyotrophic Lateral Sclerosis

2020

Objective: Musculoskeletal functional deterioration in Amyotrophic lateral sclerosis (ALS) is associated with an increase in bone fractures. The purpose of this study was to evaluate the influence of sex, ALS type, on bone quality in patients with ALS compared to healthy controls. The impact on bone health of the clinical status and some metabolic parameters was also analyzed in ALS patients.Methods: A series of 33 voluntary patients with ALS, and 66 healthy individuals matched in sex and age underwent assessment of bone mass quality using quantitative ultrasound (QUS) of the calcaneus. Ultrasonic broadband attenuation (BUA), the speed of sound (SOS), stiffness index and T-score were measur…

medicine.medical_specialtyamyotrophic lateral sclerosisOsteoporosisvitamin DPhysical strengthGastroenterologylcsh:RC346-429Pulmonary function testingFEV1/FVC ratioInternal medicinemedicineVitamin D and neurologyAmyotrophic lateral sclerosisamyotrophic lateral sclerosis bone quality neurodegeneration osteoporosis quantitative ultrasound (QUS) measurement vitamin DOssos Malaltieslcsh:Neurology. Diseases of the nervous systemBone mineralquantitative ultrasound (QUS) measurementbusiness.industryneurodegenerationBrief Research Reportmedicine.diseaseosteoporosisbone qualityNeurologyCalcaneusNeurology (clinical)business
researchProduct

Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive…

2019

Abstract Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease which is pathogenically based on the mitochondrial alteration of motor neurons, causing progressive neuron death. While ALS is characterized by enormous oxidative stress, the Mediterranean diet has been seen to have high antioxidant power. Therefore, the aim of this study is to determine how the Mediterranean diet can improve mitochondrial activity, establishing the specific nutrients and, in addition, observing the pathogenic mechanisms related to the disease that would achieve this improvement. To this end, a comprehensive review of the literature was performed using PubMed. KBs have been observed to ha…

0301 basic medicineamyotrophic lateral sclerosismitochondria ; mediterranean diet ; amyotrophic lateral sclerosis ; ketone bodiesMediterranean dietReviewslcsh:TX341-641ReviewDiseaseMitochondrionBioinformaticsmedicine.disease_causeNeuroprotection03 medical and health sciences0302 clinical medicineKetogenesisMedicineAmyotrophic lateral sclerosisbusiness.industryfood and beveragesmediterranean dietmedicine.diseasemitochondria030104 developmental biologyketone bodiesbusinessNeuron deathlcsh:Nutrition. Foods and food supply030217 neurology & neurosurgeryOxidative stressFood ScienceFood Science & Nutrition
researchProduct

Muscle Function Differences between Patients with Bulbar and Spinal Onset Amyotrophic Lateral Sclerosis. Does It Depend on Peripheral Glucose?

2021

Background: One of the pathogenic mechanisms of ALS disease is perturbed energy metabolism particularly glucose metabolism. Given the substantial difference in the severity and the prognosis of the disease, depending on whether it has a bulbar or spinal onset, the aim of the study was to determine metabolic differences between both types of ALS, as well as the possible relationship with muscle function. Materials and Methods: A descriptive, analytical, quantitative, and transversal study was carried out in hospitals and Primary Care centers in the region of Valencia, Spain. Fasting glucose and alkaline phosphatase (AP) levels in venous blood, muscle percentage, fat percentage, muscle streng…

amyotrophic lateral sclerosis:Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings]lcsh:Medicine:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Feeding Behavior::Fasting [Medical Subject Headings]DiseaseGastroenterology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicineAmyotrophic lateral sclerosisglucosespinal onset ALS:Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Phosphoric Monoester Hydrolases::Alkaline Phosphatase [Medical Subject Headings]:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Hospitals [Medical Subject Headings]0303 health sciences:Anatomy::Musculoskeletal System::Muscles [Medical Subject Headings]General MedicineVenous bloodFuerza muscular:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]PeripheralAlkaline phosphataseFosfatasa alcalinaalkaline phosphatasemedicine.medical_specialtyBarthel indexbulbar onset ALS:Diseases::Nervous System Diseases::Neurodegenerative Diseases::Motor Neuron Disease::Amyotrophic Lateral Sclerosis [Medical Subject Headings]Carbohydrate metabolismResistencia a la insulinaArticle03 medical and health sciences:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance [Medical Subject Headings]Insulin resistance:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Muscle Strength [Medical Subject Headings]Internal medicinemedicine030304 developmental biology:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]Muscle strengthbusiness.industrylcsh:RInsulin resistance:Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism [Medical Subject Headings]medicine.diseaseAtrofia muscular espinalGlucosa:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]businessEsclerosis amiotrófica lateral030217 neurology & neurosurgery
researchProduct

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

2019

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS). Methods: This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS we…

MaleVital CapacityPilot ProjectsGastroenterologylaw.inventionPlacebos0302 clinical medicineRandomized controlled triallawStilbenesMedicineAmyotrophic lateral sclerosisMedicamento1-(beta-D-Ribofuranosyl)nicotinamide chlorideMiddle AgedDrug CombinationsTreatment OutcomeNeurologyTolerabilityDisease ProgressionFemale35-Dimethoxy-4′-hydroxy-trans-stilbeneNiacinamidemedicine.medical_specialty3Investigación médicaPlaceboDouble blind03 medical and health sciencesAtrophyDouble-Blind MethodInternal medicinerandomized control studyHumansMuscle StrengthhumanAgedElectromyographybusiness.industryAmyotrophic Lateral Sclerosismedicine.diseaseAmyotrophic lateral sclerosis5-Dimethoxy-4 '-hydroxy-trans-stilbeneMétodo doble ciego1-(beta-D-Ribofuranosyl) nicotinamide chlorideRibonucleosidesNeurology (clinical)business030217 neurology & neurosurgeryEsclerosis amiotrófica lateral
researchProduct

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

2019

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health’s candidate drug EH301 in people with ALS (PALS). Methods: This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS we…

researchProduct